Ovarian Cancer Treatment Improved By Novel Medication
Main Category: Cancer / OncologyAlso Included In: Women's Health / Gynecology
Article Date: 01 Nov 2007 - 6:00 PDT
email to a friend 
printer friendly 
opinions
A new study appearing in International Journal of Gynecological Cancer states that Bevacizumab, a biologic anti-cancer agent that prevents tumor growth by interfering with the formation of new blood vessels, may have the potential to improve the efficacy of standard combination chemotherapy in ovarian cancer.
Ovarian cancer is the fifth most common cancer in women, accounting for nearly 14,000 deaths annually in the United States. Despite the use of chemotherapy treatment, nearly 70 percent of all ovarian cancer patients will eventually succumb to their disease. Consequently, studies have continued to investigate the activity of novel medications in combination with standard therapy to improve overall and disease-free survival in ovarian cancer patients.
Bevacizumab has been studied clinically and was recently approved as a treatment for metastatic colon cancer and non-small cell lung cancer. Currently, Bevacizumab is also being studied as a treatment to improve patient survival rates for breast and kidney cancers. Since Bevacizumab has a unique mechanism of action and a favorable safety profile, the medication is not associated with unreasonable levels of toxicity. However, previous studies have reported that gastro-intestinal perforations and hypertension may be a consequence of treatment involving Bevacizumab. "The results from our research suggest that the combination of Bevacizumab and standard therapy for the treatment of ovarian cancer may be promising, particularly with regard to safety and efficacy," says Dr. Bram Goldstein, co-author of the study.
###
This study is published in Vol. 17 Issue 4 of International Journal of Gynecological Cancer.
Bram H. Goldstein, Ph.D., is Senior Clinical Fellow at Gynecologic Oncology Associates-Newport Beach, Calif.
International Journal of Gynecological Cancer presents papers from throughout the global community of researchers covering many topics including basic science, epidemiology, diagnostic techniques, surgery, radiotherapy, chemotherapy, pathology and experimental studies. The Journal allows you to call on a roster of international experts for the latest research, advice, and knowledge in order to provide the best treatment for your patients. For more information, please visit http://www.blackwellpublishing.com/ijg.
Source: Sean Wagner
Blackwell Publishing Ltd.
Visit our cancer / oncology section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/87388.php>
APA
http://www.medicalnewstoday.com/releases/87388.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Visitor Opinions In Chronological Order (1)
Ovarian Cancer Treatment Improved By Novel Medication
posted by Gregory D. Pawelski on 1 Nov 2007 at 5:25 pmAngiogenesis is essential for the growth and metastasis (spread) of cancer. A growing tumor requires nutrients and oxygen (angiogenesis), which helps it grow, invade nearby tissue, and metastasize. To reach these nutrients, the tumor builds new blood vessels. In fact, growing tumors can become inactive if they can't find a new supply of nutrients.
Tumor growth is dependent on angiogenesis. Angiogenesis is dependent on VEGF. Avastin directly binds to VEGF to directly inhibit angiogenesis. Avastin works by choking off the blood vessels that provide a tumor with oxygen and nutrients. Within 24 hours of VEGF inhibition, endothelial cells have been shown to shrivel, retract, fragment and die by apoptosis. Tumors which secrete relatively low levels of VEGF might be more susceptible to an agent which works by blocking VEGF.
Angiogenesis starts when cancer cells produce a variety of growth factors and other activators (biologic molecules that begin a process). Growth factors cause endothelial cells (the cells that line blood vessels) to produce chemicals that break down the nearby tissue and the extracellular matrix (the spaces between cells). Then, the endothelial cells divide into more cells and begin building new blood vessels. Other elements, such as stromal cells (cells that form connective tissue), provide structural support for the new blood vessels.
Because angiogenesis is necessary in the growth and spread of cancer, each part of the angiogenesis process is a potential target for new cancer therapies. Avastin, used by itself and in combination with other drugs, shows that the angiogenesis-blocker boom in on. In addition to VEGF, researchers have identified a dozen other activators of angiogenesis, some of which are similar to VEGF.
There are multiple ways by which tumors can evolve that are independent of VEGF and independent of angiogenesis. Tumors can acquire a blood supply by three different mechanisms: angiogenesis; co-option of existing blood vessels; and vasculogenic mimicry. All must be inhibited to consistently starve tumors of oxygen.
Instead of growing new blood vessels, tumor cells can just grow along existing blood vessels. This process, called co-option, cannot be stopped with drugs that inhibit new blood vessel formation. Some types of cancers form channels that carry blood, but are not actual blood vessels. Drugs that target new blood vessel formation also cannot stop this process, called vasculogeneic mimicry.
The realization is that starving tumors by shutting off their blood flow requires that all three mechanisms be addressed. However, there are so many agents out there now, doctors have a confusing array of choices. They don't know how to mix them together in the right order.
Having a good tumor-drug match not only would improve survival rates, it would be cost-effective, and the high cost of the newer cancer therapies reinforces the necessity of choosing the right therapy the first time around. The tumors of different patients have different responses to chemotherapy. It requires individualized treatment based on testing the individual properties of each patient's cancer.
Drugs like Avastin can be tested with a bio-marker test called EGFRx, because the target of Avastin is not the cells themselves, but rather a hormone (VEGF) secreted by the tumor cells. The Avastin complexes with free VEGF and blocks its action. The EGFRx bio-marker can discriminate between the activity of different targeted drugs and identify situations in which it is advantageous to combine the targeted drugs with other types of cancer drugs.
A major modification of the DISC (cell death) assay allows for this study of anti-microvascular drug effects of standard and targeted agents, such as Avastin, Nexavar and Vatalanib. The assay is based upon the principle that microvascular (endothelial and associated) cells are present in tumor cell microclusters obtained from solid tumor specimens. The assay which has a morphological endpoint, allows for visualization of both tumor and microvascular cells and direct assessment of both anti-tumor and anti-microvascular drug effect. CD31 cytoplasmic staining confirms morphological identification of microcapillary cells in a tumor microcluster.
The principles and methods used in the assay include: 1. Obtaining a tissue, blood, bone marrow or malignant fluid specimen from an individual cancer patient. 2. Exposing viable tumor cells to anti-neoplastic drugs. 3. Measuring absolute in vitro drug effect. 4. Finding a statistical comparision of in vitro drug effect to an index standard, yielding an individualized pattern of relative drug activity. 5. Information obtained is used to aid in selecting from among otherwise qualified candidate drugs.
It is the only assay which involves direct visualization of the cancer cells at endpoint, allowing for accurate assessment of drug activity, discriminating tumor from non-tumor cells, and providing a permanent archival record, which improves quality, serves as control, and assesses dose response in vitro.
This kind of technique exists today and might be very valuable, especially when active chemoagents are limited in a particular disease, giving more credence to testing the tumor first. After all, cutting-edge techniques can often provide superior results over tried-and true methods that have been around for many years.
Reference: Eur J Clin Invest, Volume 37(suppl. 1):60, April 2007.
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Privacy Policy |
Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
